A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2019
Price : $35 *
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacokinetics
- Sponsors Jazz Pharmaceuticals Inc
- 13 Feb 2019 Status changed from not yet recruiting to recruiting.
- 15 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.
- 14 Sep 2018 Planned initiation date changed from 1 Aug 2018 to 1 Sep 2018.